Literature DB >> 7952645

The role of neutrophil elastase in chronic inflammation.

G Döring1.   

Abstract

Passively released or actively secreted elastase from neutrophils has been linked to the pathologic processes of a variety of inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. The serine proteinase has a broad substrate specificity and may attack a number of host proteins outside of the neutrophil, including lung elastin and fibronectin. Such a proteolysis may change the normal surrounding tissue and the protein pattern of an inflammatory focus. Additionally, it acts as a potent secretagogue in minute amounts. The reason that neutrophil elastase is present in considerable concentrations outside of the neutrophil during chronic inflammation and that the major endogenous serine proteinase inhibitor for neutrophil elastase, alpha 1-proteinase inhibitor, is easily inactivated by proteolytic and oxidative attack is unclear. Released neutrophil elastase may also be involved in regulating chronic inflammation. In a feedback mechanism, neutrophil elastase inhibits neutrophil stimulation and concomitant elastase release by cleavage of immunoglobulins, complement components, and complement receptor type 1 on neutrophils. Besides a number of harmful effects of neutrophil elastase in inflammation, the latter mechanism, although considerably impairing phagocytosis, may be beneficial particularly in the light of persistent bacterial pathogens in the human lung affected by cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952645     DOI: 10.1164/ajrccm/150.6_Pt_2.S114

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  67 in total

Review 1.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias.

Authors:  N Yoshimi; Y Ikura; Y Sugama; S Kayo; M Ohsawa; S Yamamoto; Y Inoue; K Hirata; H Itabe; J Yoshikawa; M Ueda
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

3.  Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.

Authors:  J E Hughes; J Stewart; G R Barclay; J R Govan
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 4.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer.

Authors:  Nicholas Willumsen; Lars Nannestad Jorgensen; Morten Asser Karsdal
Journal:  Cancer Biol Ther       Date:  2019-01-09       Impact factor: 4.742

6.  Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation.

Authors:  Amanda Cobos-Correa; Johanna B Trojanek; Stefanie Diemer; Marcus A Mall; Carsten Schultz
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

7.  Quantitative and qualitative differences in bronchoalveolar inflammatory cells in Pseudomonas aeruginosa-resistant and -susceptible mice.

Authors:  K Sapru; P K Stotland; M M Stevenson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 8.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Neutrophil elastase gene polymorphisms: modulators of response to therapy in childhood bronchiectasis?

Authors:  Aleksandra Nikolic; Katarina Milosevic; Srdjan Boskovic; Branimir Nestorovic
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

Review 10.  Interfering with extracellular matrix degradation to blunt inflammation.

Authors:  Philip J O'Reilly; Amit Gaggar; J Edwin Blalock
Journal:  Curr Opin Pharmacol       Date:  2008-03-17       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.